文献速递妇科

初次或间隔性肿瘤细胞减灭术时行脾切除术治疗上皮性卵巢癌:结局回顾

Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes.
PubMed 文献 · Gynecol Oncol · 2022-09-14

该研究利用机构数据库回顾2008至2018年接受初次或间隔性肿瘤细胞减灭术的III/IV期上皮性卵巢癌患者,比较行与未行脾切除术者的术后并发症及生存结局,并评估脾切除后医疗质量指标。结果显示脾切除组分期更高、手术时间和住院时间更长、输血更常见,但术后感染、再入院及总生存无差异;

要点

  • 脾切除术增加手术时间和住院时间及输血率,但未增加术后感染、再入院或总生存差异。
  • 脾切除组胰腺漏发生率为8.5%(4/47),需关注瘘管管理。

核心结论

  • 脾切除术虽增加并发症,但对能实现最佳肿瘤细胞减灭的患者仍有益处。
  • 脾切除后医疗质量改进领域包括疫苗接种、患者出院信息和及时管理胰腺瘘。

研究设计与样本

  • 回顾性队列研究,利用机构数据库GOLD CUP识别2008至2018年接受卵巢癌肿瘤细胞减灭术的患者。
  • 共纳入47例行脾切除术和454例未行脾切除术的患者。

主要发现

  • 脾切除组最终分期更高:IIIB期1例(2.1%)、IIIC期26例(55.3%)、IVA期7例(14.9%)、IVB期13例(27.7%)。
  • 脾切除组手术时间和住院时间更长,输血更常见,但术后感染、再入院或总生存无差异。
  • 脾切除组胰腺漏发生4/47例(8.5%)。

关键数值与推荐

  • 脾切除组疫苗接种记录率为89.4%(42/47)。
  • 脾切除组出院指导接受率为4.3%(2/47)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We describe post-operative complications after cytoreductive surgery with and without splenectomy for Stage III or IV epithelial ovarian cancer, and identify areas for quality improvement in post-splenectomy care. METHODS: All patients with ovarian cancer cytoreductive surgery from 2008 to 2018 were identified using an institutional database Gynecologic Oncology Longitudinal Data Collection and Utilization Program (GOLD CUP). We compared patients who had and did not have splenectomy as part of cytoreductive surgery by demographics, comorbidities, stage, operative and post-operative data, readmission rates, progression free survival, overall survival and death from disease. Quality metrics reported include receipt of post-splenectomy education handouts and encapsulated-organism vaccines. Statistical analysis was completed in STATA SE 16.0. RESULTS: We identified 47 patients who underwent splenectomy and 454 who did not during primary or interval cytoreductive surgery. Final stage was IIIB in 1 (2.1%), IIIC in 26 (55.3%), IVA in 7 (14.9%), and IVB in 13 (27.7%) patients. Those with splenectomy had significantly higher stage. Surgery duration and hospital length of stay were longer and blood transfusion more common after splenectomy, but there were no differences in post-operative infection, readmission, or overall survival. Pancreatic leaks were seen in 4/47 (8.5%) patients. Post-splenectomy vaccinations were documented in 42/47 (89.4%) patients. Only 2/47 (4.3%) received post-splenectomy discharge instructions and 3/7 (42.9%) received aspirin for platelets 1 million or more. CONCLUSIONS: While splenectomy adds morbidity, it continues to offer benefit in those patients who can achieve optimal cytoreduction. Areas for quality improvement in post-splenectomy care include receipt of vaccinations, patient discharge information, and timely pancreatic fistula management.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rush SK, Lees BF, Huang DS, et al. Splenectomy at the time of primary or interval cytoreductive surgery for epithelial ovarian carcinoma: A review of outcomes. Gynecol Oncol. 2022. PMID: 36114028. doi:10.1016/j.ygyno.2022.08.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。